Blog

TRIUMPH-1 In Print: Retatrutide's 25% Weight Loss - Plus Sore Knees And Snoring Fixed

The NEJM published the full TRIUMPH-1 dataset: 25% weight loss at 12 mg, knee osteoarthritis pain down, sleep apnoea events nearly halved. The odd details inside.

We covered the topline of retatrutide’s obesity-only phase 3 back when it dropped, but the full peer-reviewed publication is where the interesting details live. On September 29, The New England Journal of Medicine published the complete TRIUMPH-1 dataset (DOI: 10.1056/NEJMoa2604169), and the headline weight numbers are only part of the story.

What makes this paper worth a re-read is the secondary work. Lilly designed TRIUMPH-1 to test whether a 25% weight loss actually changes things people feel - arthritic knees, collapsing airways - and the results suggest it does, by margins that surprised even the trial investigators.

What the Research Says

TRIUMPH-1 randomised 2,339 adults with obesity but without diabetes to once-weekly retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks. Key results from the NEJM paper:

  • Mean weight change at 80 weeks: -17.6% on 4 mg, -23.7% on 9 mg, -25.0% on 12 mg, versus -3.9% on placebo. The two primary dose comparisons against placebo both hit p<0.001
  • In the 574 participants with knee osteoarthritis, WOMAC pain scores fell by 3.2 to 3.6 points on retatrutide versus 1.9 on placebo (hybrid estimand), a difference of 1.6 to 1.8 points at p<0.001. For a condition managed mostly with anti-inflammatories and waiting lists, that is a striking mechanical dividend from weight loss alone
  • In the 243 participants with obstructive sleep apnoea, the apnoea-hypopnea index dropped by up to 34.3 events per hour versus 9.9 on placebo. Dropping 30+ apnoeic events per hour puts many participants back into the mild-or-none band
  • The most common adverse events were gastrointestinal, consistent with the GLP-1 class

Two quirks in the published dataset are worth flagging. First, the hybrid versus ITT estimands for the OA and OSA endpoints diverge slightly in the placebo arm’s favour, and the paper shows both - a good example of how estimand choices shift the same trial’s numbers. Second, dysesthesia (abnormal skin sensations) and dose-related hypotension showed up in the higher dose groups, which we flagged in the TRIUMPH-2 diabetes readout and which now appear consistently across both phase 3 trials.

Why the Comorbidity Endpoints Matter

The incretin field has moved past the argument about whether these drugs lower weight. The argument now is what the weight loss buys. Knee osteoarthritis and sleep apnoea are two of the highest-volume, highest-cost conditions in the Australian health system - GLP-1 prescriptions got there first, but total knee replacements and CPAP machines are where the money actually goes.

Retatrutide is a GIP/GLP-1/glucagon triple receptor agonist - a different animal from tirzepatide, which we compare directly on our retatrutide research overview and tirzepatide page. The glucagon arm of the receptor profile is the likely reason the weight numbers run 8-10 points ahead of the dual agonists, and the liver-fat signals seen in the survodutide program support the same logic.

There is a real conversation to have about whether a drug trial is the right lens for knee OA in people with obesity, or whether access to structured weight management should not be gated on a prescription at all. But the data is the data: near-total pain score improvements in a third of the trial’s OA subgroup is not noise.

The Australian Angle

Retatrutide remains investigational. Lilly has indicated it plans to file with the FDA in the first quarter of 2027, and no regulator anywhere has assessed it. Australian availability, if it comes, follows years behind - and until then the only lawful source is a clinical trial. Anything sold online as retatrutide is grey or counterfeit product, and the TGA has already seized counterfeit injectables in Australia - see our counterfeit safety warning.

For where retatrutide sits against the approved incretins, our retatrutide overview runs the full comparison. For the type 2 diabetes readout, see our TRIUMPH-2 coverage linked above. And if you want to argue about estimands with people who enjoy that sort of thing, join the Telegram community.

Sources

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.